Hdl Handle:
http://hdl.handle.net/10147/139338
Title:
Update on smoking cessation therapies.
Authors:
Glynn, Deirdre A; Cryan, John F; Kent, Pauline; Flynn, Robert A; Kennedy, Marcus P
Affiliation:
Department of Medicine, Sligo General Hospital, Republic of Ireland.
Citation:
Update on smoking cessation therapies. 2009, 26 (4):369-82 Adv Ther
Journal:
Advances in therapy
Issue Date:
Apr-2009
URI:
http://hdl.handle.net/10147/139338
DOI:
10.1007/s12325-009-0022-9
PubMed ID:
19399385
Additional Links:
http://www.ncbi.nlm.nih.gov/pubmed?term=19399385
Abstract:
As a reflection of an exponential increase in smoking rates throughout the world during the last century, the economic and human burden of mortality and morbidity related to smoking is now clearly defined. Smoking cessation is associated with health benefits for people of all ages. In this paper we provide a comprehensive review of current licensed pharmacological smoking cessation agents including efficacy and safety profiles, with comparisons of individual therapies available. Furthermore, we offer a prospective on the need for further testing of other agents including novel avenues of therapy.
Item Type:
Article
Language:
en
Description:
As a reflection of an exponential increase in smoking rates throughout the world during the last century, the economic and human burden of mortality and morbidity related to smoking is now clearly defined. Smoking cessation is associated with health benefits for people of all ages. In this paper we provide a comprehensive review of current licensed pharmacological smoking cessation agents including efficacy and safety profiles, with comparisons of individual therapies available. Furthermore, we offer a prospective on the need for further testing of other agents including novel avenues of therapy.
MeSH:
Antidepressive Agents, Second-Generation; Benzazepines; Bupropion; Cost of Illness; Drug Approval; Humans; Morbidity; Nicotine; Nicotinic Agonists; Quinoxalines; Safety; Smoking; Smoking Cessation; Treatment Outcome; United States; World Health
ISSN:
1865-8652

Full metadata record

DC FieldValue Language
dc.contributor.authorGlynn, Deirdre Aen
dc.contributor.authorCryan, John Fen
dc.contributor.authorKent, Paulineen
dc.contributor.authorFlynn, Robert Aen
dc.contributor.authorKennedy, Marcus Pen
dc.date.accessioned2011-08-10T14:39:24Z-
dc.date.available2011-08-10T14:39:24Z-
dc.date.issued2009-04-
dc.identifier.citationUpdate on smoking cessation therapies. 2009, 26 (4):369-82 Adv Theren
dc.identifier.issn1865-8652-
dc.identifier.pmid19399385-
dc.identifier.doi10.1007/s12325-009-0022-9-
dc.identifier.urihttp://hdl.handle.net/10147/139338-
dc.descriptionAs a reflection of an exponential increase in smoking rates throughout the world during the last century, the economic and human burden of mortality and morbidity related to smoking is now clearly defined. Smoking cessation is associated with health benefits for people of all ages. In this paper we provide a comprehensive review of current licensed pharmacological smoking cessation agents including efficacy and safety profiles, with comparisons of individual therapies available. Furthermore, we offer a prospective on the need for further testing of other agents including novel avenues of therapy.en
dc.description.abstractAs a reflection of an exponential increase in smoking rates throughout the world during the last century, the economic and human burden of mortality and morbidity related to smoking is now clearly defined. Smoking cessation is associated with health benefits for people of all ages. In this paper we provide a comprehensive review of current licensed pharmacological smoking cessation agents including efficacy and safety profiles, with comparisons of individual therapies available. Furthermore, we offer a prospective on the need for further testing of other agents including novel avenues of therapy.-
dc.language.isoenen
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed?term=19399385en
dc.subject.meshAntidepressive Agents, Second-Generation-
dc.subject.meshBenzazepines-
dc.subject.meshBupropion-
dc.subject.meshCost of Illness-
dc.subject.meshDrug Approval-
dc.subject.meshHumans-
dc.subject.meshMorbidity-
dc.subject.meshNicotine-
dc.subject.meshNicotinic Agonists-
dc.subject.meshQuinoxalines-
dc.subject.meshSafety-
dc.subject.meshSmoking-
dc.subject.meshSmoking Cessation-
dc.subject.meshTreatment Outcome-
dc.subject.meshUnited States-
dc.subject.meshWorld Health-
dc.titleUpdate on smoking cessation therapies.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medicine, Sligo General Hospital, Republic of Ireland.en
dc.identifier.journalAdvances in therapyen
dc.description.provinceConnacht-
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.